RU2004110041A - Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика - Google Patents

Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика Download PDF

Info

Publication number
RU2004110041A
RU2004110041A RU2004110041/15A RU2004110041A RU2004110041A RU 2004110041 A RU2004110041 A RU 2004110041A RU 2004110041/15 A RU2004110041/15 A RU 2004110041/15A RU 2004110041 A RU2004110041 A RU 2004110041A RU 2004110041 A RU2004110041 A RU 2004110041A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
gabapentin
aminoamide
acceptable derivative
Prior art date
Application number
RU2004110041/15A
Other languages
English (en)
Other versions
RU2295337C2 (ru
Inventor
Патриси САЛЬВАТИ (IT)
Патрисия Сальвати
Орьетта ВЕНЕРОНИ (IT)
Орьетта ВЕНЕРОНИ
Роберто МАЙ (IT)
Роберто Май
Руджеро ФАРЬЕЛЛО (IT)
Руджеро ФАРЬЕЛЛО
Лука БЕНАТТИ (IT)
Лука Бенатти
Original Assignee
Ньюрон Фармасьютикалс Спа (It)
Ньюрон Фармасьютикалс Спа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюрон Фармасьютикалс Спа (It), Ньюрон Фармасьютикалс Спа filed Critical Ньюрон Фармасьютикалс Спа (It)
Publication of RU2004110041A publication Critical patent/RU2004110041A/ru
Application granted granted Critical
Publication of RU2295337C2 publication Critical patent/RU2295337C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

1. Фармацевтическая композиция, содержащая габапентин или прегабалин или их фармацевтически приемлемое производное, и α-аминоамид, выбранный из группы, состоящей из (S)-(+)-2-[4-(2-фторбензилокси)бензиламино]пропанамида, (R)-(-)-2-[4-бензилоксибензиламино]-3-фенил-N-метилпропанамида и (S)-(+)-2-[4-(3-фторбензилокси)бензиламино]-N-метилпропанамида, в этом случае или в виде одного изомера, или в виде их смеси, или их фармацевтически приемлемого производного, где α-аминоамид и габапентин, или прегабалин, или их фармацевтически приемлемые производные находятся в соотношении, основанном на соотношении их соответствующих значений ED50, где соотношение находится в пределах, соответственно, от примерно 1:1 до примерно 30:1 или от примерно 1:1 до примерно 1:30.
2. Фармацевтическая композиция по п.1, где α-аминоамид и габапентин или прегабалин находятся в соотношении, основанном на соотношении их соответствующих значений ED50, где соотношение находится в пределах, соответственно, от примерно 1:1 до примерно 9:1 или от примерно 1:1 до примерно 1:9.
3. Фармацевтическая композиция по п.1, где α-аминоамид и габапентин или прегабалин находятся в соотношении, основанном на соотношении их соответствующих значений ED50, где соотношение находится в пределах, соответственно, от примерно 1:1 до примерно 3:1 или от примерно 1:1 до примерно 1:3.
4. Фармацевтическая композиция по п.2, где α-аминоамид и габапентин или прегабалин находятся в соотношении, основанном на соотношении их соответствующих значений ED50, где соотношение находится в пределах, соответственно, от примерно 1:1 до примерно 3:1 или от примерно 1:1 до примерно 1:3.
5. Фармацевтическая композиция по п.1, содержащая габапентин или его фармацевтически приемлемое производное и α-аминоамид или его фармацевтически приемлемое производное.
6. Фармацевтическая композиция по п.2, содержащая габапентин или его фармацевтически приемлемое производное и α-аминоамид или его фармацевтически приемлемое производное.
7. Фармацевтическая композиция по п.3, содержащая габапентин или его фармацевтически приемлемое производное и α-аминоамид или его фармацевтически приемлемое производное.
8. Фармацевтическая композиция по п.4, содержащая габапентин или его фармацевтически приемлемое производное и α-аминоамид или его фармацевтически приемлемое производное.
9. Фармацевтическая композиция по любому из предыдущих пунктов, содержащая габапентин или его фармацевтически приемлемое производное и где α-аминоамид представляет собой (S)-(+)-2-[4-(2-фторбензилокси)бензиламино]пропанамид или его фармацевтически приемлемое производное.
10. Применение фармацевтической композиции по любому из предыдущих пунктов для получения лекарственного препарата для лечения боли.
RU2004110041/15A 2001-09-03 2002-08-09 Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика RU2295337C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01121069 2001-09-03
EP01121069.7 2001-09-03

Publications (2)

Publication Number Publication Date
RU2004110041A true RU2004110041A (ru) 2005-03-10
RU2295337C2 RU2295337C2 (ru) 2007-03-20

Family

ID=8178510

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004110041/15A RU2295337C2 (ru) 2001-09-03 2002-08-09 Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика

Country Status (21)

Country Link
US (2) US8084447B2 (ru)
EP (1) EP1423168B1 (ru)
JP (1) JP4350508B2 (ru)
KR (1) KR100890875B1 (ru)
CN (1) CN1274306C (ru)
AT (1) ATE317280T1 (ru)
AU (1) AU2002333374B2 (ru)
BR (1) BRPI0212298B8 (ru)
CA (1) CA2459470C (ru)
DE (1) DE60209152T2 (ru)
DK (1) DK1423168T3 (ru)
ES (1) ES2253579T3 (ru)
HK (1) HK1070305A1 (ru)
IL (2) IL160523A0 (ru)
MX (1) MXPA04002009A (ru)
NO (1) NO331298B1 (ru)
NZ (1) NZ531586A (ru)
PT (1) PT1423168E (ru)
RU (1) RU2295337C2 (ru)
SI (1) SI1423168T1 (ru)
WO (1) WO2003020273A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019898B1 (ru) * 2007-12-11 2014-07-30 Ньюрон Фармасьютикалс С.П.А. Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
WO2000061188A1 (en) 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002333374B2 (en) 2001-09-03 2007-03-22 Newron Pharmaceuticals S.P.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an (alpha)- aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE602004025586D1 (de) * 2003-08-25 2010-04-01 Newron Pharm Spa Alpha-aminoamid derivate zur verwendung als anti-inflammatorische wirkstoffe
EP1533302A1 (en) * 2003-11-21 2005-05-25 Newron Pharmaceuticals S.p.A. Histidine derivatives
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
ATE523484T1 (de) * 2005-05-10 2011-09-15 Teva Pharma Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure
CN100410242C (zh) * 2005-06-23 2008-08-13 江苏恩华药业股份有限公司 普瑞巴林中间体及其制备方法
WO2007035890A1 (en) 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. An asymmetric synthesis of ( s ) - ( + ) -3- (aminomethyl) -5-methylhexanoic acid
EP1798236A1 (en) * 2005-12-13 2007-06-20 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Process for the preparation of 3-pyridyl-1-hydroxyethylidene-1,1- biphosphonic acid and hydrated forms thereof
DK1963280T3 (en) 2005-12-22 2015-12-14 Newron Pharm Spa 2-phenylethylamine derivatives by calcium and / or sodium channel
WO2007147491A1 (en) * 2006-06-19 2007-12-27 Newron Pharmaceuticals S.P.A. Process for the production of 2- [4 - ( 3- and 2-flu0r0benzyl0xy) benzylamin0] propan amides
EP2155663B1 (en) 2007-06-15 2017-11-29 Newron Pharmaceuticals S.p.A. Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
HUE030504T2 (en) 2010-04-27 2017-05-29 Newron Pharm Spa Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers
AU2019381269A1 (en) * 2018-09-04 2021-03-18 Minerva Neurosciences, Inc. Methods of using a phenoxypropylamine compound to treat pain

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658967A (en) * 1966-06-23 1972-04-25 Ici Ltd Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
CH480308A (de) * 1966-08-11 1969-10-31 Ciba Geigy Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4311853A (en) * 1979-02-06 1982-01-19 The Radiochemical Centre Limited Selenium derivatives of thyroxine and tri-iodothyronine
DE3050800C2 (ru) 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be
US4267354A (en) * 1979-04-25 1981-05-12 E. R. Squibb & Sons, Inc. Substituted amides having antiinflammatory activity and intermediates
GR68380B (ru) * 1979-06-01 1981-12-28 Wellcome Found
ZA805476B (en) 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
EP0144853B1 (en) * 1983-11-21 1990-09-26 Fujisawa Pharmaceutical Co., Ltd. Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US4725619A (en) 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB2216515A (en) * 1988-03-04 1989-10-11 Nippon Shinyaku Co Ltd Acylphenol derivatives
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
DE3928488A1 (de) 1989-08-29 1991-03-07 Standard Elektrik Lorenz Ag Interferometrisches messsystem
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
EP0525360B1 (en) 1991-07-30 1998-03-25 Korea Research Institute Of Chemical Technology Novel phenylacetamide derivatives and processes for the preparation thereof
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9306899D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5482964A (en) * 1994-10-11 1996-01-09 Warner-Lambert Company Substituted phenoxyhydroxypropyl amines as central nervous system agents
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
KR0147963B1 (ko) 1995-01-10 1998-08-17 강박광 엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
US5688830A (en) * 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO1998007447A1 (en) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
CA2264231A1 (en) 1996-08-29 1998-03-05 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
EP1132082A1 (en) * 1996-11-05 2001-09-12 Head Explorer ApS Use of substances capable of blocking the production of glutamate for treating tension-type headache
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
FR2756738B1 (fr) 1996-12-06 1999-02-12 Sod Conseils Rech Applic Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
IL119890A (en) 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
GB9706730D0 (en) 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives
EP0986540B1 (en) 1997-04-22 2005-02-16 Euro-Celtique S.A. The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6593368B2 (en) * 1997-09-08 2003-07-15 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
CA2310664C (en) * 1997-11-21 2008-03-11 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
GB9727521D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
CA2309354A1 (en) 1998-01-23 1999-07-29 Leslie Magnus-Miller Gabapentin and its derivatives for the treatment of muscular and skeletal pain
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
AU754681B2 (en) 1998-02-04 2002-11-21 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
KR20010071776A (ko) 1998-07-09 2001-07-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 대상포진의 치료를 위한 ｇａｂａ 유사체 및항바이러스제를 포함하는 제약 조성물
PL345340A1 (en) 1998-07-09 2001-12-17 Warner Lambert Co Compositions comprising gaba analogs and caffeine
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
IL145508A0 (en) 1999-03-26 2002-06-30 Euro Celtique Sa Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same
WO2000061188A1 (en) 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
PT1202725E (pt) 1999-07-22 2007-07-11 Universuty Of Rochester Método para tratar sintomas de alteração hormonal, incluindo afrontamentos.
WO2001010381A2 (en) * 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
GB9930079D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
WO2001098779A2 (en) 2000-06-19 2001-12-27 Merck Frosst Canada & Co. Methods of identifying gabab receptor subtype-specific agonists
EP1229332A3 (en) 2001-02-02 2004-07-28 Warner-Lambert Company In vitro assay for testing gabapentinoid activity
AU2002333374B2 (en) 2001-09-03 2007-03-22 Newron Pharmaceuticals S.P.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an (alpha)- aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019898B1 (ru) * 2007-12-11 2014-07-30 Ньюрон Фармасьютикалс С.П.А. Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты

Also Published As

Publication number Publication date
BR0212298A (pt) 2004-09-14
NO20040907L (no) 2004-05-14
EP1423168A2 (en) 2004-06-02
RU2295337C2 (ru) 2007-03-20
HK1070305A1 (en) 2005-06-17
IL160523A (en) 2009-02-11
MXPA04002009A (es) 2004-07-08
DE60209152T2 (de) 2006-08-03
JP2005504782A (ja) 2005-02-17
US20040248978A1 (en) 2004-12-09
BRPI0212298B1 (pt) 2015-11-03
US8084447B2 (en) 2011-12-27
AU2002333374B2 (en) 2007-03-22
WO2003020273A2 (en) 2003-03-13
JP4350508B2 (ja) 2009-10-21
IL160523A0 (en) 2004-07-25
CN1274306C (zh) 2006-09-13
CA2459470A1 (en) 2003-03-13
WO2003020273A3 (en) 2003-09-04
PT1423168E (pt) 2006-05-31
DE60209152D1 (de) 2006-04-20
NO331298B1 (no) 2011-11-21
KR100890875B1 (ko) 2009-03-31
BRPI0212298B8 (pt) 2021-05-25
EP1423168B1 (en) 2006-02-08
NZ531586A (en) 2005-09-30
US8710040B2 (en) 2014-04-29
CA2459470C (en) 2010-10-12
DK1423168T3 (da) 2006-05-15
CN1556720A (zh) 2004-12-22
KR20040034686A (ko) 2004-04-28
US20120142777A1 (en) 2012-06-07
SI1423168T1 (sl) 2006-06-30
AU2002333374A2 (en) 2003-03-18
ATE317280T1 (de) 2006-02-15
ES2253579T3 (es) 2006-06-01

Similar Documents

Publication Publication Date Title
RU2004110041A (ru) Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
EA200701123A1 (ru) Способ очистки транс-(-)-δ-тетрагидроканнабинола и транс-(+)-δ-тетрагидроканнобинола
EA200801492A1 (ru) Фармацевтическое применение замещенных амидов
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
JP2005504782A5 (ru)
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2001009076A3 (en) Retinoids for the treatment of emphysema
EA200400707A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
SE9804126D0 (sv) New pharmaceutical composition
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
EA200600998A1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
HUP0302521A2 (hu) Neurotrop tacrolimus analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk